semi-allogeneic MHC class II dendritic cell vaccine

The **semi-allogeneic MHC class II dendritic cell vaccine** is an investigational cancer immunotherapy comprising bone marrow-derived dendritic cells (BMDCs) engineered to be semi-allogeneic, featuring intact syngeneic MHC class I (e.g., H2Db) for tumor antigen presentation to CD8+ T cells and mutant allogeneic MHC class II (e.g., from bm12 mice) to stimulate alloreactive CD4+ T helper cells. Pulsed with tumor-specific peptides like gp10025–33 or E743–77, it enhances antitumor CD8+ CTL responses via early-stage allogeneic CD4+ help, outperforming syngeneic or MHC class I semi-allogeneic DC vaccines in suppressing B16-F10 melanoma and TC-1 HPV+ tumor growth in mice. Efficacy is CD4+ T cell-dependent early on but improved at later stages by Treg or CD4+ depletion, enabling "off-the-shelf" use without patient-specific derivation while retaining MHC-matched antigen presentation.[1][2][3]

Other names

MHC class II semiallogeneic BMDC vaccinepeptide-pulsed MHC class II semiallogeneic BMDC vaccine